New England Research & Management Inc. Lowers Position in Roche Holding AG (OTCMKTS:RHHBY)

New England Research & Management Inc. reduced its stake in Roche Holding AG (OTCMKTS:RHHBY) by 7.3% during the second quarter, HoldingsChannel.com reports. The fund owned 13,875 shares of the company’s stock after selling 1,100 shares during the quarter. New England Research & Management Inc.’s holdings in Roche were worth $481,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of RHHBY. AlphaMark Advisors LLC purchased a new position in Roche during the first quarter worth $34,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Roche during the fourth quarter valued at about $53,000. First Horizon Advisors Inc. lifted its position in Roche by 19.8% during the fourth quarter. First Horizon Advisors Inc. now owns 2,066 shares of the company’s stock valued at $75,000 after acquiring an additional 342 shares during the last quarter. GAMMA Investing LLC purchased a new position in Roche in the fourth quarter worth $146,000. Finally, Waldron Private Wealth LLC purchased a new position in Roche during the 4th quarter worth $294,000.

Roche Stock Performance

Shares of OTCMKTS:RHHBY traded down $0.08 during midday trading on Tuesday, reaching $39.26. 1,105,697 shares of the company’s stock traded hands, compared to its average volume of 2,445,272. The company has a fifty day simple moving average of $35.72 and a two-hundred day simple moving average of $33.41. Roche Holding AG has a 1 year low of $29.20 and a 1 year high of $41.15. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.75.

Wall Street Analysts Forecast Growth

RHHBY has been the subject of a number of research analyst reports. The Goldman Sachs Group assumed coverage on shares of Roche in a report on Thursday, May 30th. They issued a “sell” rating for the company. Deutsche Bank Aktiengesellschaft raised shares of Roche from a “sell” rating to a “hold” rating in a report on Friday, May 17th. Two equities research analysts have rated the stock with a sell rating and five have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $40.00.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.